Gene Expressions and High Lymphocyte Count May Predict Durable Clinical Benefits in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Immune Checkpoint Inhibitors

Gene Expressions and High Lymphocyte Count May Predict Durable Clinical Benefits in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Immune Checkpoint Inhibitors

Background: Not all patients with advanced non-small cell lung cancer (NSCLC) benefit from immune checkpoint inhibitors (ICIs). Therefore, we aimed to assess the predictive potential of gene expression profiling (GEP), peripheral immune cell counts, and clinical characteristics. Methods: The primary...

Full description

Bibliographic Details
Main Authors: Mette T. Mouritzen, Morten Ladekarl, Henrik Hager, Trine B. Mattesen, Julie B. Lippert, Malene S. Frank, Anne K. Nøhr, Ida B. Egendal, Andreas Carus
Format: Article
Language:English
Published: MDPI AG 2023-09-01
Series:Cancers
Subjects:
immune checkpoint inhibitors
non-small cell lung cancer
biomarkers
gene expression analysis
lymphocyte count
liver metastases
Online Access:https://www.mdpi.com/2072-6694/15/18/4480

Internet

https://www.mdpi.com/2072-6694/15/18/4480

Similar Items